Rakuten Medical vs Schrödinger
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rakuten Medical is a biotech developing photoimmunotherapy cancer treatment using its Illuminox platform (cetuximab sarotalocan), approved in Japan for head and neck cancer and in clinical trials globally; listed on Tokyo Stock Exchange (TYO: 4707);
About
Rakuten Medical, Inc. is a biotechnology company founded by Yoshihiro Seto in 2006 (as Aspyrian Therapeutics, renamed Rakuten Medical after acquisition by Rakuten Group) and headquartered in San Diego, California, with primary R&D and commercial operations in Japan. The company is focused on developing cancer treatments using its proprietary photoimmunotherapy (PIT) platform, branded as Illuminox. Photoimmunotherapy combines a targeted antibody conjugated to a photoabsorber dye that, when activated by near-infrared light, selectively destroys cancer cells in the illuminated region while minimizing damage to surrounding healthy tissue — a precision oncology approach distinct from traditional chemotherapy or immunotherapy.
Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.
About
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.